Articles

A new technique of intraductal meibomian gland probing using disposable cannulas of various lengths appears highly effective in providing quick and lasting relief from inflammatory sysmptoms of obstructive meibomian gland disease.

Patients share their postoperative experiences and the dramatic changes in their lives bought about by undergoing refractive lens surgery. Patients had either high myopia, hyperopia and/or severe astigmatism and each received the AT.LISA 366D, a one-piece, 4 haptic multifocal IOL and each has found a new lease of life.

Before and after cataract surgery

Application of genetic knowledge holds huge potential for the future and some believe that it has potential to become larger than the pharmaceutical market. Here Dr Alward examines what it has offered for the understanding and future treatment of glaucoma. Until recently, breakthroughs in glaucoma genetics emerged from painstaking family research, with the discovery of LOXL1 being the exception.

A question and answer session with a canaloplasty expert.

Evaluation of a new value-based treatment approach for wet AMD.

Are the years of research and advocacy at last reaping rewards?

An oil-in-water and a corticosteroid were both effective in eliminating the signs and symptoms of lid wiper epitheliopathy after a 1-month active treatment phase in a recent study. Improvement was effectively maintained with the emollient eye drops in all patients over a 12-month period.

Leadership and evidence-based approaches to alleviate the burden of blindness

The Seeing is Believing initiative at Stardard Chartered Bank

The background to the Egyptian Menia study

World Sight Day is an international day of awareness to focus attention on the global issue of avoidable blindness and visual impairment. This year the theme is Gender and Eye Health – equal access to care

The use of hydroxypropyl cellulose can significantly improve the symptoms of dry eye, resulting in increased quality of life.

A recent study showed that moderate to sever dry eye disease can be best treated with anti-inflammatory medications such as topical cyclosporine. According to one ophthalmologist, cyclosporine can significantly limit progression of dry eye disease and should be considered a 'go-to' therapy for this patient population.

An interview with Dr Mark Tomalla about his experience with the Crystalens HD IOL.

Whilst VISION 2020 is a global initiative it always had a focus on Europe too

Drs Belin and Ambrosio's Enhanced Ectasia module is a keratoconus index, based on pachy

Professor Auffarth of Heidelberg University Eye Clinic reports on the results of his implantation of the LENTIS Mplus and explains how the lens works using a new unique optical principle.

Changes of culture and strategy at Pfizer are good news for ophthalmology

A comparison of an older nanoliter osometer and a newer osometer shows that both devices are effective in measuring tear osmolarity and produce comparable measurements.

A Kenyan doctor's perspective

A pioneering model of community health

In the second of a two-part article Drs Lombardi and Belilli present the results of a patient suffering with a wet maculopathy affecting both eyes.

A look at the VISION 2020 Gender Discussion Group

The MECTIZAN donation programme to fight river blindness

Forty five millon people are blind worldwide, yet 80% of blindness is avoidable

References

According to a report in the August issue of Archives of Ophthalmology, there are eight factors that may predict whether a choroidal nevus-a benign, flat, pigmented growth inside the eye and beneath the retina-may develop into melanoma.

Allergan Inc. expects its ketorolac tromethamine ophthalmic solution 0.45% (Acuvail) to be available in the United States in September. The preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the treatment of pain and inflammation after cataract surgery and received FDA approval at the end of July, the company announced.

Results from the Omeros Corporation for the Phase I/Phase II clinical trial of OMS302, a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis) are said to be promising.